Given the aggressiveness of the disease and the urgent need for novel and more effective targeted therapies for infant KMT2Ar ALL patients, my ongoing project is focused on identifying and validating novel therapeutic compounds through drug repurposing, which could be immediately translatable to the clinic to offer these young patients an alternative treatment.